Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer

NCT04258644 is registered in ClinicalTrials.gov with Beijing Friendship Hospital as lead sponsor.

NCT NCT04258644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04258644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer
Lead sponsor
Beijing Friendship Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
March 1, 2020
Completion date
February 28, 2023
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer